Evogliptin (hydrochloride)
Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation[1].
Product Specifications
CAS Number
1246960-27-9
Product Name Alternative
DA-1229 (hydrochloride)
UNSPSC
12352005
Target
Dipeptidyl Peptidase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/evogliptin-hydrochloride.html
Smiles
O=C1NCCN([C@@H]1COC(C)(C)C)C(C[C@@H](CC2=CC(F)=C(C=C2F)F)N)=O.Cl
Molecular Formula
C19H27ClF3N3O3
Molecular Weight
437.88
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 4
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD20 / MS4A1 (B-Cell Marker) (rIGEL/773), 0.2mg/mL
